Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)
March 18, 2024 4:04 PM EDTCiti analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).
The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'
March 15, 2024 6:11 AM EDTH.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $425.00 (from $405.00) while maintaining a Buy rating.
The analyst comments "Rezdiffra approved with a strong label that represents the "best case" for Madrigal's commercial opportunity. Yesterday, in a widely anticipated decision, Madrigal announced that the FDA has granted accelerated approval to Rezdiffra (resmetirom) as the first ever drug for MASH (formerly, NASH). We view the label as broad and highly supportive of the use of Rezdiffra as a foundational therapy in NASH patients with significant fibrosis. Specifically, the... More
Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at Citi
March 15, 2024 3:49 AM EDTCiti analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $389.00 (from $382.00) while maintaining a Buy rating.
The analyst comments "Madrigal announced that Rezdiffra (Resmetirom) was approved as the first therapy to treat non-cirrhotic non-alcoholic steatohepatitis (NASH, also known as metabolic... More
Madrigal Pharma (MDGL) option implied volatility into FDA approval
March 14, 2024 3:51 PM EDTMadrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.
... MoreMadrigal Pharma (MDGL): FDA Approves rezdiffra
March 14, 2024 3:45 PM EDT(Updated - March 14, 2024 3:52 PM EDT)
Madrigal Pharma (NASDAQ: MDGL): FDA Approves rezdiffra - website.
Rezdiffra indicated in conjunction with diet, exercise for treatment of adults with NASH with moderate to advanced liver fibrosis.... More
Madrigal Gets FDA Approval For NDA For Rezdiffra
March 14, 2024 3:45 PM EDTMadrigal Gets FDA Approval For NDA For Rezdiffra
... MoreMadrigal Pharma (MDGL) Halted, News Pending
March 14, 2024 3:30 PM EDTMadrigal Pharma (NASDAQ: MDGL) Halted, News Pending
